Clinical trial
Pregabalin In Partial Seizures Extension Study
NCT00143130 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00143130 |
|---|---|
| Title | Pregabalin In Partial Seizures Extension Study |
| Official title | Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial |
| Acronym | PREPS EXT |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Seizures |
| Intervention type | Drug |
| Interventions | Pregabalin |
| Enrollment | 227 |
| Start date | Apr 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 28, 2021 |
| Countries | Belgium, Finland, France, Poland, Portugal, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: